[From marker expression to individual therapy of patients with bladder cancer].

Abstract

Urothelial carcinoma of the bladder is a tumor entity with a heterogenous clinical course. At one end of the spectrum, patients are treated for low-grade carcinomas, which are likely to reccur but show low rates of tumor progression. At the other end, patients suffer from noninvasive or early invasive high-grade carcinomas. In these cases, risk-adapted treatment decisions are more complicated. The following article gives an overview of research activities on bladder cancer with the aim to individualize treatment of patients with bladder cancer.

• Authors: F Vom Dorp, C Börgermann, T Jäger, M Becker, K W Schmid, H Rübben
• Journal: Der Urologe. Ausg. A (Urologe A) Vol. 47 Issue 9 Pg. 1167-70 (Sep 2008) ISSN: 0340-2592 [Print] Germany
• Vernacular Title: Von der Markerexpression zur individuellen Prognoseabschätzung urothelialer Neoplasien.
• PMID: 18712513 (Publication Type: English Abstract, Journal Article, Review)

Chemical References

• Biomarkers, Tumor

Topics

• Biomarkers, Tumor (analysis)
• Carcinoma, Transitional Cell (pathology, therapy)
• Combined Modality Therapy
• Disease Progression
• Humans
• Neoplasm Invasiveness
• Neoplasm Recurrence, Local (pathology, therapy)
• Neoplasm Staging
• Prognosis
• Research
• Tissue Array Analysis
• Urinary Bladder (pathology)
• Urinary Bladder Neoplasms (pathology, therapy)